- Companies
- Galvanize Therapeutics
Galvanize Therapeutics Valuation, Funding & Investors
Galvanize Therapeutics is valued at $650M as of September 2025.
Last Galvanize Therapeutics valuation
$650M
Series C · Sep 2025
Last Galvanize Therapeutics funding round
$100M
Series C · Sep 2025
Cumulative funding Galvanize Therapeutics raised
$243M
across 3 funding rounds
Key investors in Galvanize Therapeutics
Fidelity
Apple Tree Partners
Gilmartin Capital LLC
intuitive
Norwest
T. Rowe Price
About Galvanize Therapeutics
Galvanize Therapeutics is a Boston-headquartered medical device company developing pulsed field ablation platforms for respiratory, cardiac, and oncology applications. Its portfolio features the Galaxy system for bronchoscopic lung volume reduction in chronic obstructive pulmonary disease patients and the Pulse Field Ablation platform for atrial fibrillation. The company targets solid tumors through non-thermal tissue ablation and holds FDA Breakthrough Device Designation for its cardiac rhythm management tools. Backed by Apple Tree Partners since its 2022 inception, Galvanize Therapeutics advances therapies across U.S. clinical sites and international partnerships.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$650M (Sep 2025)
Galvanize Therapeutics Valuation
Galvanize Therapeutics is currently valued at $650M, based on its Series C in September 2025.
The $100M round was led by Sofinnova Partners, with participation from Fidelity, Gilmartin Capital LLC, Longaeva Partners, Janus Henderson, Norwest and 6 other investors.
Galvanize Therapeutics valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Sep 2025 | Series C | $650M |
Galvanize Therapeutics Funding History
Galvanize Therapeutics has raised a total of $243M across 3 funding rounds.
Galvanize Therapeutics' first fundraising round was a $43M undisclosed-stage round in March 2019. The most recent completed round was a $100M Series C in September 2025.
Galvanize Therapeutics funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Sep 2025 | Series C | Sofinnova Partners (lead); Fidelity; Gilmartin Capital LLC; Longaeva Partners; Janus Henderson; Norwest; T. Rowe Price; Apple Tree Partners; Perceptive Xontogeny Venture Fund; intuitive; Ally Bridge Group; Elevage Medical Technologies | $100M | $650M | Galvanize Therapeutics, Inc. is a commercial-stage medical technology company based in Redwood City, California, pioneering pulsed electric field (PEF) therapies as a non-drug approach for treating solid tumors in oncology and chronic bronchitis, the leading cause of chronic obstructive pulmonary disease (COPD). The company has developed products including Aliya® PEF for solid tumors and RheOx® for chronic bronchitis. On September 3, 2025, Galvanize closed an oversubscribed $100 million Series C financing round led by Sofinnova Partners, with participation from new investors such as Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors, Longaeva Partners, and NVP Associates, LLC, alongside existing investors including Apple Tree Partners, Fidelity Management & Research Company, T. Rowe Price, Gilmartin Capital, and Intuitive Surgical. The post-money valuation for this round was $650 million. Proceeds from the financing are designated to expand commercial reach, advance clinical and development activities for its PEF platform, and broaden the footprint of its therapies targeting underserved patients reliant on pharmaceutical treatments. As part of the transaction, Antoine Papiernik from Sofinnova Partners, Zack Scott from NVP Associates (or Norwest), and David Lewis from Gilmartin Capital joined the company's board of directors. Sofinnova Partners, a Paris-based European life sciences venture capital firm founded in 1972 managing over €4 billion, highlighted the investment as backing a breakthrough platform addressing millions of underserved patients. Galvanize positions its PEF technologies as transformative alternatives to drug-based treatments for chronic diseases, with the Series C funding enabling scaling of commercial operations and pipeline advancement. The round's oversubscribed nature and blue-chip investor participation underscore strong market confidence in the company's traction and potential in oncology and pulmonology medtech sectors. |
| Sep 2022 | Series B | Fidelity (lead); Gilmartin Capital LLC; Apple Tree Partners; intuitive | $100M | - | Galvanize Therapeutics raised $100M in a Series B funding round on September 15, 2022, with investors including Fidelity Investments (lead), Apple Tree Partners, Gilmartin Capital, and Intuitive. The company develops a pulsed electric field (PEF) platform for treating cancer and chronic lung diseases, including Aliya PEF for solid tumors and RheOx therapy for chronic bronchitis. The funding supported advancement of clinical and development activities for the PEF platform, a non-thermal, non-pharmacologic intervention using short electrical pulses to target pathologic cells. Subsequent rounds included a $100M Series C on September 3, 2025, led by Sofinnova Partners with participation from Fidelity, Apple Tree Partners, Gilmartin Capital, Intuitive Surgical, and others, bringing total raised to over $256M across multiple rounds. Galvanize's platform showed clinical promise, such as the RheSolve trial with 34% reduction in COPD exacerbations over 24 months. The company operates in the medical devices and biotech space, focusing on underserved patients in oncology and pulmonology. |
| Mar 2019 | Undisclosed stage | - | $43M | - | Search results detail later financings, such as a $100 million Series B in September 2022 led by Fidelity Management & Research Company with participation from Intuitive Surgical, Apple Tree Partners, and Gilmartin Capital to advance the Aliya Pulsed Electric Field platform for chronic bronchitis, cardiac arrhythmias, solid tumors, and drug delivery. The company, formed by merging Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics under Apple Tree Partners, focuses on non-thermal electrical pulses to treat diseases. A $100 million oversubscribed Series C followed in September 2025, led by Sofinnova Partners, to expand commercial activities for Aliya PEF in oncology and RheOx for chronic bronchitis. |
Who has invested in Galvanize Therapeutics?
12 investors have backed Galvanize Therapeutics across its funding rounds, including Fidelity, Apple Tree Partners, Gilmartin Capital LLC, intuitive, Norwest and T. Rowe Price.
Lead investors include Sofinnova Partners and Fidelity.
Galvanize Therapeutics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Sep 2022 | ||
| 2 | Participant | Sep 2022 | ||
| 2 | Participant | Sep 2022 | ||
| 2 | Participant | Sep 2022 | ||
| 1 | Participant | Sep 2025 | ||
| 1 | Lead | Sep 2025 | ||
| 1 | Participant | Sep 2025 | ||
| 1 | Participant | Sep 2025 | ||
| 1 | Participant | Sep 2025 | ||
| 1 | Participant | Sep 2025 | ||
This data is available for Pro users. Sign up to see all 12 Galvanize Therapeutics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Galvanize Therapeutics
Galvanize Therapeutics has acquired 2 companies to date.
Last acquisition by Galvanize Therapeutics was on September 15th 2022. Galvanize Therapeutics acquired Gala Therapeutics for undisclosed valuation.
Latest Acquisitions by Galvanize Therapeutics
| Description | - | Galaxy Medical is a Salt Lake City-based developer of cardiology devices including stents and balloon catheters. It holds FDA clearances for its Galaxy Stent system used in peripheral artery treatments. The company supplies hospitals in the US and Latin America since 2010. |
| HQ Country | ||
| HQ City | - | San Francisco, CA |
| Deal Date | 15 Sep 2022 | 15 Sep 2022 |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Galvanize Therapeutics acquisitions and their M&A valuation multiples. Start Free Trial | ||
Galvanize Therapeutics Competitors
Galvanize Therapeutics competitors include listed companies like Sunmax Biotechnology, UltraGreen.ai and MiMedx Group, and private ones like MindMaze, Geneoscopy and Hyperice.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $8M | - | $1.5B | 187.5x | ||
| Publicly listed | $64M | $35M | $670M | - | ||
| Private | - | - | $630M | - | ||
| Publicly listed | $138M | $78M | $672M | 2.9x | ||
| Publicly listed | $419M | $78M | $684M | 1.8x | ||
| Private | - | - | $700M | - |
Galvanize Therapeutics Public Comps
Galvanize Therapeutics is still privately-owned, but its public comps include Lumibird, SS Innovations, AngioDynamics, Sunmax Biotechnology, UltraGreen.ai, Cytek Biosciences, MiMedx Group, Oculis Holding, Nanosonics and Barco.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $263M | $48M | 2.8x | 2.7x | 15.5x | 12.7x | |||
| $42M | ($7M) | 15.5x | 12.0x | (92.4x) | (71.9x) | |||
| $320M | ($13M) | 1.8x | 1.8x | (44.5x) | 34.3x | |||
| $64M | $35M | 10.2x | - | 18.6x | - | |||
| $138M | $78M | 3.4x | 2.9x | 6.1x | 4.7x | |||
| $201M | ($24M) | 2.2x | 2.1x | (18.4x) | (78.1x) | |||
| $419M | $78M | 1.4x | 1.8x | 7.2x | 21.0x | |||
| - | ($121M) | - | 283.0x | (2.8x) | (3.3x) | |||
This data is available for Pro users. Sign up to see all Galvanize Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Galvanize Therapeutics
| When was Galvanize Therapeutics founded? | Galvanize Therapeutics was founded in 2015. |
| Where is Galvanize Therapeutics headquartered? | Galvanize Therapeutics is headquartered in San Francisco, CA, United States. |
| Is Galvanize Therapeutics publicly listed? | No, Galvanize Therapeutics is a private, VC-backed company. |
| What is Galvanize Therapeutics' valuation? | Galvanize Therapeutics was last valued at $650M in its Series C in September 2025. |
| How much funding has Galvanize Therapeutics raised? | Galvanize Therapeutics has raised $243M across 3 funding rounds. |
| What was Galvanize Therapeutics' last funding round? | Galvanize Therapeutics' last funding round was a $100M Series C in September 2025, led by Sofinnova Partners. |
| Who are Galvanize Therapeutics' investors? | Galvanize Therapeutics' investors include Fidelity, Gilmartin Capital LLC, Apple Tree Partners, intuitive, Longaeva Partners, Sofinnova Partners, Janus Henderson, Norwest, T. Rowe Price, Perceptive Xontogeny Venture Fund and 2 others. |
| Which companies are comparable to Galvanize Therapeutics? | Companies comparable to Galvanize Therapeutics include MindMaze, Sunmax Biotechnology, Geneoscopy, UltraGreen.ai, MiMedx Group and Hyperice. |
| How many companies has Galvanize Therapeutics acquired? | Galvanize Therapeutics has acquired 2 companies, including Gala Therapeutics and Galaxy Medical. |
See companies similar to Galvanize Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




